nach oben

Reviews in Endocrine and Metabolic Disorders

Erschienen in:

06.10.2020

The continuum between GH deficiency and GH insensitivity in children

verfasst von: Martin O. Savage, Helen L. Storr, Philippe F. Backeljauw

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

The continuum of growth hormone (GH)-IGF-I axis defects extends from severe to mild GH deficiency, through short stature disorders of undefined aetiology, to GH insensitivity disorders which can also be mild or severe. This group of defects comprises a spectrum of endocrine, biochemical, phenotypic and genetic abnormalities. The extreme cases are generally easily diagnosed because they conform to well-studied phenotypes with recognised biochemical features. The milder cases of both GH deficiency and GH insensitivity are less well defined and also overlap with the group of short stature conditions, labelled as idiopathic short stature (ISS). In this review the continuum model, which plots GH sensitivity against GH secretion, will be discussed. Defects causing GH deficiency and GH insensitivity will be described, together with the use of a diagnostic algorithm, designed to aid investigation and categorisation of these defects. The continuum will also be discussed in the context of growth-promoting endocrine therapy.

Collett-Solberg PF, Ambler G, Backeljauw PF, Bidlingmaier M, Biller BMK, Boguszewski MCS, et al. Diagnosis, genetics and therapy of short stature in children: a growth hormone research society international perspective. Horm Res Paediatr. 2019;92:1–14.PubMedCrossRef

Storr HL, Chatterjee S, Foley C, Metherell LA, Backeljauw PF, Rosenfeld RG, et al. Non-classical growth hormone insensitivity (GHI): Characterization of mild abnormalities of GH action. Endocr Rev. 2019;40:475–505.CrossRef

Cohen P. Problems with reclassification of insulin-like growth factor-I production and action disorders. J Clin Endocrinol Metab. 2006;91:4235–6.PubMedCrossRef

Rosenfeld RG. Insulin-like growth factors and the basis of growth. New Eng J Med. 2003;349:2184–6.PubMedCrossRef

Savage MO, Burren CP, Rosenfeld RG. The continuum of growth hormone-IGF-I axis defects causing short stature: diagnostic and therapeutic challenges. Clin Endocrinol. 2010;72:721–8.CrossRef

Ranke MB. Defining insulin-like growth factor deficiency. Horm Res. 2006;65(Suppl 1):9–14.PubMedCrossRef

Wit JM, Clayton PE, Rogol AD, Savage MO, Cohen P. Idiopathic short stature: definition, epidemiology, and diagnostic evaluation. Growth Hormon IGF Res. 2008;18:89–110.CrossRef

Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH research society. J Clin Endocrinol Metab. 2000;85:3990–3.

Wit JM, Van Unen H. Growth in infants with neonatal growth hormone deficiency. Arch Dis Child. 1992;67:920–4.PubMedPubMedCentralCrossRef

10.

Maghnie M, Rossi A, di Iorgi N, Gastaldi R, Tortori-Donati P, Lorini R. Hypothalamic-pituitary magnetic resonance imaging in growth hormone deficiency. Expert Rev Endocrinol Metab. 2006;1:413–23.PubMedCrossRef

11.

Ranke MB, Wit JM. Growth hormone – past present and future. Nat Rev Endocrinol. 2018;14:285–300.PubMedCrossRef

12.

Roth J, Glick SM, Yalow RS, Berson SA. Hypoglycaemia: a potent stimulus to secretion of human growth hormone. Science. 1963;140:987–8.PubMedCrossRef

13.

Wagner IV, Paetzold C, Gausche R, Vogel M, Loerner A, Thiery J, et al. Clinical evidence-based cut-off limits for GH stimulation tests in children with a back-up of results with reference to mass spectrometry. Eur J Endocrinol. 2014;171:389–97.PubMedCrossRef

14.

Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Pediatr. 2016;86:361–97.CrossRef

15.

Blum WF, Alherbish A, Alsagheir A, El Awwa A, Kaplan W, Koledova E, et al. The growth hormone-insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders. Endocr Conn. 2018;7:R212–22.CrossRef

16.

Deal C, Hasselmann C, Pfäffle RW, Zimmermann AG, Quigley CA, Child CJ, et al. Associations between pituitary imaging abnormalities and clinical and biochemical phenotypes in children with congenital growth hormone deficiency: data from an international observational study. Horm Res Paediatr. 2013;79:283–92.PubMedCrossRef

17.

Cohen RAD, Deal CL, Saenger P, Reiter EO, Ross J, et al. Consensus Statement on Diagnosis and Treatment of Children with Idiopathic Short Stature. A Summary of the GRS/LWPES/ESPE Workshop. J Clin Endocrinol Metab. 2008;93:4210–7.PubMedCrossRef

18.

Hauer NN, Popp B, Schoeller E, Schuhmann S, Heath KE, Hisado-Oliva A, et al. Clinical relevance of systematic phenotyping and exome sequencing in patients with short stature. Genet Med. 2018;20:630–8.PubMedCrossRef

19.

Dauber A. Genetic testing for the child with short stature – has the time come to change our diagnostic paradigm? J Clin Endocrinol Metab. 2019;104:2766–9.PubMedCrossRef

20.

Dassa Y, Crosnier H, Chevignard M, Viaud M, Personnier C, Fletchner I, et al. Pituitary deficiency and precocious puberty after childhood severe traumatic brain injury: a long-term follow-up prospective study. Eur J Endocrinol. 2019;180:281–90.PubMedCrossRef

21.

Attie KM, Carlsson LM, Rundle AC, Sherman BM. Evidence for partial growth hormone insensitivity among patients with idiopathic short stature. The National Cooperative Growth Study. J Pediatr. 1995;127:244–50.PubMedCrossRef

22.

Sjoberg M, Salazar T, Espinosa C, Dagnino A, Avila A, Eggers M, et al. Study of GH sensitivity in chilean patients with idiopathic short stature. J Clin Endocrinol Metab. 2001;86:4375–81.PubMedCrossRef

23.

Pedicelli S, Peschiaroli E, Violi E, Cianfarani S. Controversies in the definition and treatment of idiopathic short stature (ISS). J Clin Res Pediatr Endocrinol. 2009;1:105–15.PubMedPubMedCentralCrossRef

24.

Carlsson LM, Attie KM, Compton PG, Vitangcol RV, Merimee TJ. Reduced concentration of serum growth hormone-binding protein in children with idiopathic short stature. National Cooperative Growth Study. J Clin Endocrinol Metab. 1994;78:1325–30.PubMed

25.

Buckway CK, Guevara-Aguirre J, Pratt KL, Burren CP, Rosenfeld RG. The IGF-I generation test revisited: a marker of GH sensitivity. J Clin Endocrinol Metab. 2001;86:5176–83.PubMedCrossRef

26.

Hujeirat Y, Hess O, Shalev S, Tenenbaum-Rakover Y. Growth hormone receptor sequence changes do not play a role in determining height in children with idiopathic short stature. Horm Res. 2006;65:210–6.PubMed

27.

David A, Hwa V, Metherell LA, Netchine I, Camacho-Hubner C, Clark AJ, et al. Evidence for a continuum of genetic, phenotypic, and biochemical abnormalities in children with growth hormone insensitivity. Endocr Rev. 2011;32:472–97.PubMedCrossRef

28.

Woods KA, Dastot F, Preece MA, Clark AJL, Postel-Vinay MC, Chatelain PG, et al. Phenotype: genotype relationships in growth hormone insensitivity syndrome. J Clin Endocrinol Metab. 1997;82:3529–35.PubMed

29.

Vairamani K, Merjaneh L, Casano-Sancho P, Sanli ME, David A, Metherell LA, et al. Dominant negative GH receptor mutations expands the Spectrum of GHI and IGF-1 deficiency. J Endocr Soc. 2017;1:345–58.PubMedPubMedCentralCrossRef

30.

Ayling RM, Ross RJ, Towner P, Von Laue S, Finidori J, Moutoussamy S, et al. A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nat Genet. 1997;16:13–4.PubMedCrossRef

31.

Iida K, Takahashi Y, Kaji H, Nose O, Okimura Y, Abe H, et al. Growth hormone (GH) insensitivity syndrome with high serum GH-binding protein levels caused by a heterozygous splice site mutation of the GH receptor gene producing a lack of intracellular domain. J Clin Endocrinol Metab. 1998;83:531–7.PubMed

32.

Metherell LA, Akker SA, Munroe PB, Rose SJ, Caulfield M, Savage MO, et al. Pseudoexon activation as a novel mechanism for disease resulting in atypical growth-hormone insensitivity. Am J Hum Genet. 2001;69:641–6.PubMedPubMedCentralCrossRef

33.

Chatterjee S, Shapiro L, Rose SJ, Mushtaq T, Clayton PE, Ten SB, et al. Phenotypic Spectrum and responses to recombinant human IGF-1 (rhIGF-1) therapy in patients with homozygous Intronic Pseudoexon growth hormone receptor mutations. Eur J Endocrinol. 2018;178:481–9.PubMedCrossRef

34.

Chatterjee S, Cottrell E, Rose SJ, Mushtaq T, Maharaj AV, Williams J, et al. Growth hormone receptor (GHR) gene transcript heterogeneity may explain phenotypic variability in patients with homozygous GHR Pseudoexon (6Ψ) mutation. Endocr Conn. 2020;9:211–22. https://doi.org/10.1530/EC-20-0026.CrossRef

35.

Heath KE, Argente J, Barrios V, Pozo J, Diaz-Gonzalez F, Martos-Moreno GA, et al. Primary acid-labile subunit deficiency due to recessive IGFALS mutations results in postnatal growth deficit associated with low circulating insulin growth factor (IGF)-I, IGF binding protein-3 levels, and hyperinsulinemia. J Clin Endocrinol Metab. 2008;93:1616–24.PubMedCrossRef

36.

Dauber A, Munoz-Calvo MT, Barrios V, Domene HM, Kloverpris S, Serra-Juhe C, et al. Mutations in pregnancy-associated plasma protein A2 cause short stature due to low IGF-I availability. EMBO Mol Med. 2016;8:363–74.PubMedPubMedCentralCrossRef

37.

Klammt J, Neumann D, Gevers EF, Andrew SF, Schwartz ID, Rockstroh D, et al. Dominant-negative STAT5B mutations cause growth hormone insensitivity with short stature and mild immune dysregulation. Nat Commun. 2018;9:2105. https://doi.org/10.1038/s41467-018-04521-0.CrossRefPubMedPubMedCentral

38.

van Duyvenvoorde HA, van Setten PA, Walenkamp MJ, van Doorn J, Koenig J, Gauguin L, et al. Short stature associated with a novel heterozygous mutation in the insulin-like growth factor 1 gene. J Clin Endocrinol Metab. 2010;95:E363–7.PubMedCrossRef

39.

van Duyvenvoorde HA, Kempers MJ, Twickler TB, van Doorn J, Gerver WJ, Noordam C, et al. Homozygous and heterozygous expression of a novel mutation of the acid-labile subunit. Eur J Endocrinol. 2008;159:113–20.PubMedCrossRef

40.

Fofanova-Gambetti OV, Hwa V, Wit JM, Domene HM, Argente J, Bang P, et al. Impact of heterozygosity for acid-labile subunit (IGFALS) gene mutations on stature: results from the international acid-labile subunit consortium. J Clin Endocrinol Metab. 2010;95:4184–91.PubMedCrossRef

41.

Isik E, Haliloglu B, van Doorn J, Demirbilek H, Scheltinga SA, Losekoot M, et al. Clinical and biochemical characteristics and bone mineral density of homozygous, compound heterozygous and heterozygous carriers of three novel IGFALS mutations. Eur J Endocrinol. 2017;176:657–67.PubMedCrossRef

42.

Inoue-Lima TH, Vasques GA, Scalco RC, Nakaguma N, Mendonca BB, Arnhold IJ, et al. IGF-I assessed by pubertal status has the best positive predictive power for GH deficiency diagnosis in peripubertal children. J Pediatr Endocrinol Metab. 2019;32:173–9.PubMedCrossRef

43.

Cianfarani S, Liguori A, Boemi S, Maghnie M, Lughetti L, Wasniewska M, et al. Inaccuracy of insulin-like growth factor (IGF) binding protein (IGFBP)-3 assessment in the diagnosis of growth hormone (GH) deficiency from childhood to young adulthood: association to low GH dependency of IGF-II and presence of circulating IGFBP-3 18-kilodalton fragment. J Clin Endocrinol Metab. 2005;90:6028–34.PubMedCrossRef

44.

Hjortebjerg R, Frystyk J. Determination of IGFs and their binding proteins. Best Pract Res Clin Endocrinol Metab. 2013;27:771–81.PubMedCrossRef

45.

Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jorgensen K, et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab. 1994;78:744–52.PubMed

46.

Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelsen KF, et al. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab. 1995;80:2534–42.PubMed

47.

Coutant R, Dorr HG, Gleeson H, Argente J. Diagnosis of endocrine disease: limitations of the IGF1 generation test in children with short stature. Eur J Endocrinol. 2012;166:351–7.PubMedCrossRef

48.

Blum WF, Ranke MB, Savage MO, Hall K. Insulin-like growth factors and their binding proteins in patients with growth hormone receptor deficiency: suggestions for new diagnostic criteria. Kabi Pharmacia study group on insulin-like growth factor-I treatment in growth hormone insensitivity syndromes. Acta Paediatr Suppl. 1992;383:125–6.PubMed

49.

Selva KA, Buckway CK, Sexton G, Pratt KL, Tjoeng E, Guevara-Aguirre J, et al. Reproducibility in patterns of IGF generation with special reference to idiopathic short stature. Horm Res. 2003;60:237–46.PubMed

50.

Midyett LK, Rogol AD, Van Meter QL, Frane J, Bright GM. Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2010;95:611–9.PubMedCrossRef

51.

Kriström B, Aronson AF, Gustafsson J, Halldin M, Ivarsson SA, Nilsson N-O, et al. Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature. J Clin Endocrinol Metab. 2009;94:483–90.PubMedCrossRef

52.

Bang P, Bjerknes R, Dahlgren J, Dunkel L, Justafsson J, Juul A, et al. A comparison of different definitions of growth response in short prepubertal children treated with growth hormone. Horm Res Paediatr. 2012;75:335–45.CrossRef

Titel: The continuum between GH deficiency and GH insensitivity in children
verfasst von: Martin O. Savage
Helen L. Storr
Philippe F. Backeljauw
Publikationsdatum: 06.10.2020
Verlag: Springer US
Erschienen in: Reviews in Endocrine and Metabolic Disorders / Ausgabe 1/2021
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-020-09590-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Disruption of the GHRH receptor and its impact on children and adults: The Itabaianinha syndrome

Pharmacogenomics applied to recombinant human growth hormone responses in children with short stature

Mouse models of growth hormone insensitivity

Insights from the clinical phenotype of subjects with Laron syndrome in Ecuador

Growth hormone deficiency and replacement therapy in adults: Impact on survival